Video: Carterra has been Selected by the Gates Foundation to Help Solve the COVID-19 Pandemic
Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
Biocompare Article on How Epitope Binning Streamlines Discovery and Exploits Diversity
Epitope binning screens and characterizes antibodies in one step. Studying kinetics, affinity, and epitope relationships in high throughput allows characterization of antibody libraries generated against a specific antigen through B cell cloning, phage display, or hybridoma technologies.
Carterra® Closes Financing Round for Continued Growth of the LSA™ Platform for Next Generation Antibody Discovery
Additional Resources Will Support New Product Development and Global Expansion
2019 Carterra Symposia
View the slides of the presentations from the therapeutic antibody revolution in the post genomics era symposia.
Bristol-Myers Squibb, Boehringer Ingelheim and Other Biotechnology Companies to Present Use of Carterra’s Next Generation Antibody Screening Technology at Symposia Across the US and Europe
Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.
GEN Article: A Therapeutic Antibody Characterization Trinity Accelerates Drug Development
The three core applications of high throughput SPR that form the antibody characterization trinity are capture kinetics, epitope binning, and epitope mapping. Together, they provide a comprehensive characterization of antibody libraries with minimal sample consumption, enabling more confident decisions to be made earlier and obviating the need for preliminary ELISA screening.
BioTechniques Article on Accelerating Biotherapeutic Discovery with High Throughput SPR
High throughput SPR is revolutionizing antibody screening for drug discovery, allowing screening and characterization to be accomplished in the same step, at the very beginning of the discovery process.
SLAS Invites Yasmina Abdiche to Present Current Advancements in Antibody Discovery
Accelerate library-to-lead triage of antibody libraries using high throughput SPR.